Want to see VYGR full AI Analyst Report?

Voyager Therapeutics (VYGR) Price & Analysis

1,397 Followers

VYGR Stock Chart & Stats

$3.10

$0.01(0.32%)

At close: Jul 24 4:00 PM EDT

$3.10

$0.01(0.32%)

Day’s Range― - ―

52-Week Range$2.88 - $5.55

Previous CloseN/A

Volume484.46K

Average Volume (3M)714.30K

Market Cap

$183.68M

Enterprise Value$122.74

Total Cash (Recent Filing)$141.48M

Total Debt (Recent Filing)$34.57M

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Jul 30, 2026

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.98

Shares Outstanding60,421,288

10 Day Avg. Volume752,857

30 Day Avg. Volume714,297

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)1.18

Price to Sales (P/S)5.71

P/FCF Ratio-1.71

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$17.00

Price Target Upside448.39% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.74

Revenue Forecast (FY)$39.27M

Bulls Say, Bears Say

Bulls Say

Platform & BBB DeliveryIdentification of ALPL as a mediator of IV-to-CNS transport is a durable platform strength. It supports systemic, one-time dosing with broad CNS distribution, lowering translational risk versus unknown delivery mechanisms and giving a repeatable technical edge for neurological gene therapies.

IND Clearance & Clinical PlanRegulatory clearance to begin human trials is a structural milestone that shifts program risk profile. An active clinical path enables human safety and biomarker data generation, de-risks development steps, and creates durable optionality for partnerships, milestones and future capital events.

Conservative LeverageLow debt provides durable financial flexibility for a pre-revenue biotech. Limited fixed obligations reduce near-term insolvency risk, making equity or milestone-based financing the main lever and preserving capacity to fund R&D or pursue partnerships without high interest burdens.

Bears Say

High Cash BurnSustained negative operating and free cash flow at this scale creates persistent funding need. Over months this forces reliance on external capital, increases dilution risk, constrains the ability to advance multiple programs, and heightens execution risk if markets or partners delay financing.

Deep UnprofitabilityVery large negative net margins show operating spend far exceeds high gross profit, reflecting R&D intensity without commercial revenue. Continued losses erode equity and returns, limiting resilience to setbacks and raising the bar for future non-dilutive funding or self-sustaining operations.

Authorized Shares ExpansionNear-doubling authorized shares is a structural governance change that increases potential dilution capacity. While it provides financing flexibility, it signals anticipated equity raises and can dilute shareholder economics over time if used to fund continuing cash burn or partner-less development.

Voyager Therapeutics News

Voyager Therapeutics presents six-month toxicology data for VY1706

Voyager Therapeutics (VYGR) presented six-month good laboratory practice toxicology data for VY1706, the company’s investigational gene therapy targeting...

17d ago

VYGR

Voyager Therapeutics: Buy Rating Reaffirmed and $25 Price Target Maintained on Tau Therapy Leadership and Upcoming Clinical Milestones

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics today and set a price target...

11d ago

VYGR

Voyager Therapeutics advances tau-silencing gene therapy program

Voyager Therapeutics ( ($VYGR) ) has provided an update. On July 13, 2026, Voyager Therapeutics presented three- and...

17d ago

VYGR

Voyager Therapeutics Expands Authorized Shares After Stockholder Vote

The latest update is out from Voyager Therapeutics ( ($VYGR) ). On June 9, 2026, Voyager Therapeutics, Inc....

2M ago

VYGR

Voyager Therapeutics announces FDA clearance for VY1706 IND application

Voyager Therapeutics (VYGR) announced that the FDA has cleared its investigational new drug, or IND, application for VY1706,...

2M ago

VYGR

Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy

The latest announcement is out from Voyager Therapeutics ( ($VYGR) ). On June 1, 2026, Voyager Therapeutics, Inc....

2M ago

VYGR

Voyager Therapeutics: Advancing CNS Gene Therapy Pipeline and TRACER Platform Underpin Buy Rating and Unchanged $25 Price Target

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Voyager Therapeutics today and set a price target...

2M ago

VYGR

Voyager awarded new mission management contract with Exobiosphere

Voyager Technologies and Exobiosphere announced a mission management contract on the International Space Station that marks a concrete...

3M ago

VYGR

Voyager Therapeutics presents GLP for toxicology data for VY1706

Voyager Therapeutics (VYGR) presented three-month good laboratory practice, or GLP, toxicology data for VY1706, the Company’s investigational tau...

3M ago

VYGR

Voyager Therapeutics Warns of Broad Risk Exposure and Uncertain Outlook in Latest SEC Filings

Voyager Therapeutics Inc. (VYGR) has disclosed a new risk, in the Regulation category. Voyager Therapeutics Inc. is exposed...

3M ago

VYGR

Analyst Reaffirms Buy on Voyager Therapeutics as Strong Cash Runway and Advancing Neurology Pipeline Set Up Multiple 2026 Catalysts

TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating on...

3M ago

VYGR

Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)

Reports Q1 revenue $2.59M, consensus $8.79M. “As the ‘Year of Tau’ for Alzheimer’s disease continues to unfold, Voyager...

3M ago

VYGR

Voyager Therapeutics management to meet with Oppenheimer

Meeting to be held on April 28 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

3M ago

VYGR

Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes

Voyager Therapeutics ( ($VYGR) ) has shared an update. On April 15, 2026, Voyager Therapeutics, Inc. announced that...

3M ago

VYGR

VYGR FAQ

What was Voyager Therapeutics Inc.’s price range in the past 12 months?

Voyager Therapeutics Inc. lowest stock price was $2.88 and its highest was $5.55 in the past 12 months.

What is Voyager Therapeutics Inc.’s market cap?

Voyager Therapeutics Inc.’s market cap is $183.68M.

When is Voyager Therapeutics Inc.’s upcoming earnings report date?

Voyager Therapeutics Inc.’s upcoming earnings report date is Jul 30, 2026 which is today.

How were Voyager Therapeutics Inc.’s earnings last quarter?

Currently, no data Available

Is Voyager Therapeutics Inc. overvalued?

According to Wall Street analysts Voyager Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Voyager Therapeutics Inc. pay dividends?

Voyager Therapeutics Inc. does not currently pay dividends.

What is Voyager Therapeutics Inc.’s EPS estimate?

Voyager Therapeutics Inc.’s EPS estimate is -0.48.

How many shares outstanding does Voyager Therapeutics Inc. have?

Voyager Therapeutics Inc. has 60,421,288 shares outstanding.

What happened to Voyager Therapeutics Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Voyager Therapeutics Inc.?

Currently, no hedge funds are holding shares in VYGR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Voyager Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-37.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Voyager Therapeutics Inc.

Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.

Voyager Therapeutics (VYGR) Earnings & Revenues

Historic Earnings Reports

VYGR Stock 12 Month Forecast

Average Price Target

$17.00

▲(448.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.6,5.246153846153846,6.892307692307693,8.538461538461538,10.184615384615384,11.83076923076923,13.476923076923077,15.123076923076923,16.76923076923077,18.415384615384614,20.06153846153846,21.70769230769231,23.353846153846156,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.6,4.630769230769231,5.661538461538462,6.692307692307693,7.723076923076924,8.753846153846155,9.784615384615385,10.815384615384616,11.846153846153847,12.876923076923077,13.907692307692308,14.938461538461539,15.969230769230771,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.6,3.9384615384615387,4.276923076923077,4.615384615384615,4.953846153846154,5.292307692307693,5.63076923076923,5.969230769230769,6.307692307692308,6.6461538461538465,6.984615384615385,7.323076923076924,7.661538461538461,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >